E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
chronic venous incufficiency |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10047220 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Main objective :the objective of this study is to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous incufficiency (CVI, CEAP Classification: Clinical Class 3 and 4a) |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Male or female 2.18 years of age or older 3.CVI, Clinical Class 3 and Class 4a according to the CEAP classification: severe oedema and stem varicosis and (hypo- / hyperpigmentation or eczema or atrophy) 4.Severe oedema: the pretibial oedema will be determined at the screening and baseline visit. The skin (approximately 20 cm from the floor) of the more affected leg will be pressed for approximately 30 seconds and thereafter a picture will be taken for documentation. The monitors will collect the pictures at the monitoring visits. 5.Stable oedema: difference of less than 150 g between screening and baseline as determined by water displacement method 6.Willing and able to give written informed consent prior to participation in the study
|
|
E.4 | Principal exclusion criteria |
A.Concomitant diseases 1Decompensated cardiac insufficiency according to the New York Heart Association (NYHA) classification III and IV for cardiac patients, see Appendix 5 2.Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc) 3.Severe skin changes, e.g. lipodermatosclerosis or ulcus 4.Peripheral arterial disease (ankle/arm pressure index < 0.9) 5.Current acute phlebitis or thrombosis. Patients with a healed postthrombotic syndrome, who do not currently receive a medical treatment, can be included in the study. 6.Renal insufficiency (serum creatinine > 1.5 mg/dl) 7.Liver disease (clinically significant deviation from normal reference range for SGPT and SGOT) 8.Other diseases: hyper- or hypocalcaemia, malignancies 9.Anamnestic indications of diabetic microangiopathy or polyneuropathy 10.Drug and/or alcohol abuse 11.Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months 12.Immobility 13.Avalvulia 14.Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans) 15.State after pulmonary embolism 16.Recognised hypersensitivity to the trial drug ingredients 17.Current florid venous ulcus 18.Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.
B. Previous treatments 1.Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures. If the compression therapy / wearing of support stockings is stopped two weeks prior to the intake of study medication, the patient can be included. 2.Treatment with venous drugs within the last 2 weeks prior to the intake of study medication 3.Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication
C. Concomitant treatment/non-drug therapy exclusion criteria 1.Other venous drugs apart from the trial medication 2.Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry 3.Extensive use of laxatives 4.Major surgery requiring full anaesthesia 5.Nitrates, ergot alkaloids and diuretics
D. Other exclusion criteria 1.Previously studied under this protocol 2.Participation in another clinical trial within the previous 90 days or during the present study 3.Patient is investigator, co-investigator, study nurse in this study or is a relative of the investigator, co-investigator, or study nurse in this study 4.Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only) 5.Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial 6.Patients in a bad general health state according to the investigator’s judgement
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in limb volume determination at day 84 (water displacement method)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial will be the last patient visit (visit 5) , scheduled 84 days after randomisation. Just in case an adverse event still exist at visit 5, a follow up visit will be scheduled. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 8 |